We completed human 18F PET nuclear imaging clinical study with pHLIP® peptide at the Memorial Sloan Kettering Cancer Center. The ClinicalTrials.gov identifier is NCT04054986, https://clinicaltrials.gov/ct2/show/NCT04054986
Fluorescence-guided surgical clinical trial with pHLIP® ICG imaging agent will be initiated at the Memorial Sloan Kettering Cancer Center in 2021.
Cybrexa Therapeutics (pHLIP, Inc sublicensee) announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex™-exatecan, where alphalex™ consists of a pHLIP® peptide and linker), the company’s lead therapeutic candidate. The ClinicalTrials.gov identifier is NCT04902872, https://clinicaltrials.gov/ct2/show/NCT04902872